References
- 1. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Prevention Program (DPP). https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/diabetes prevention-program-dpp
- 2. American Diabetes Association Professional Practice Committee for Diabetes. Prevention or delay of diabetes and associated comorbidities: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S50–S60. https://doi.org/10.2337/dc26-S003
- 3. Державний реєстр лікарських засобів України. Глюкофаж XR (Glucophage XR): реєстраційне посвідчення № UA/3994/02/01. 2025. https://drlz.moz.gov.ua/register/product/17834
- 4. Knowler WC, Doherty L, Edelstein SL, et al. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial. Lancet Diabetes Endocrinol. 2025;13(6):469–481. https://doi.org/10.1016/S2213-8587(25)00022-1
- 5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865.
- 6. Adler AI, Coleman RL, Leal J, et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024;404(10448):145–155. https://doi.org/10.1016/S0140-6736(24)00537-3
- 7. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes — 2025. https://idf.org/t2d-cpr-2025 https://international-diabetes-federation.s3.eu-west 1.amazonaws.com/media/uploads/2025/05/IDF_Rec_2025.pdf
